MHRA-100174-PIP01-21

Key Facts

Active Substance
Active Substance:
  • Encequidar
Invented Name
Paxorlea
PIP Number MHRA-100174-PIP01-21
Pharmaceutical form(s)
Pharmaceutical form(s):
  • All forms
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
  • Treatment of breast cancer
  • Treatment of soft tissue sarcoma
Route(s) of administration
Route(s) of administration:
  • All routes of administration
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Encequidar.pdf
Published Date 17/11/2021